CRISPR Activation (CRISPRa) Screening Service
CRISPRa is an effective CRISPR tool that enables targeted upregulation of endogenous genes without modifying the DNA sequence. Compared to conventional cDNA overexpression, CRISPRa activates genes at their native loci, maintaining natural regulation and isoform diversity. It also supports high-throughput screening to identify genes that impact key phenotypes like proliferation, differentiation, or drug response. At Creative Biolabs, we provide an all-inclusive CRISPRa screening service featuring premium sgRNA libraries, efficient lentiviral delivery systems, and advanced data analysis solutions, and deliver tailored, reliable results for your research goals.
What is CRISPR Activation (CRISPRa) Screening?
CRISPRa is an innovative and highly precise gene regulation technology that drives the robust transcription of targeted genes without making irreversible modifications to the underlying DNA sequence. Unlike traditional CRISPR-Cas9 systems that utilize a wild-type Cas9 nuclease to create double-strand breaks, CRISPRa employs a catalytically "dead" Cas9 (dCas9). This dCas9 variant retains its programmable RNA-guided DNA-binding capability but lacks endonuclease activity. By fusing dCas9 to highly active tripartite transcriptional activation domains—such as VP64, p65, and Rta (the VPR system), or utilizing synergistic systems like SAM (Synergistic Activation Mediator) and SunTag—the complex is precisely directed to the promoter or enhancer regions of a target gene via highly specific single guide RNAs (sgRNAs).
Figure 1. CRISPR screens can identify regulators of the Cancer-immunity cycle.1
Overcoming the Limitations of Traditional Gain-of-Function Models
For decades, researchers relied on Open Reading Frame (ORF) or cDNA overexpression systems to conduct gain-of-function studies. While useful, these conventional methods suffer from severe biological and technical limitations that frequently derail gene therapy research. Our CRISPRa Screening platform effectively bypasses these bottlenecks:
| Feature | Traditional cDNA/ORF Overexpression | Creative Biolabs CRISPRa Screening |
|---|---|---|
| Expression Context | Ectopic/Artificial (driven by exogenous promoters) | Endogenous/Native (driven from natural genomic loci) |
| Transcript Variants | Limited to a single cloned splice variant | Comprehensive (expresses natural splice variants and isoforms) |
| Size Constraints | Highly restricted (large genes >5kb are difficult to package into lentivirus) | No limit (sgRNAs are small; can activate genes of any size) |
| Multiplexing Capability | Extremely difficult (requires multiple large plasmids) | Highly scalable (multiple sgRNAs can be easily co-delivered) |
| Expression Levels | Often artifactual, toxic super-physiological levels | Physiologically relevant (controlled by natural cellular machinery) |
| Library Feasibility | Cumbersome to generate and maintain genome-wide libraries | Highly efficient via streamlined oligonucleotide synthesis |
Transformative Applications in Gene Therapy and Research
Creative Biolabs has optimized our CRISPRa screening pipeline to directly support the rigorous demands of preclinical gene therapy development, immuno-oncology, and target discovery. Our platform enables you to achieve critical milestones across diverse biological applications:
Drug Resistance and Sensitivity Profiling
A major hurdle in oncology and targeted therapeutics is acquired drug resistance. Through genome-wide CRISPRa screening, you can systematically overexpress thousands of genes in the presence of your drug candidate. Cells that survive lethal doses of the compound indicate that the upregulated gene confers resistance. This allows for the rapid identification of resistance biomarkers and the strategic design of synergistic combination therapies.
Immuno-Oncology and Tumor Microenvironment (TME) Modulation
Understanding how tumor cells evade immune surveillance is critical for developing next-generation CAR-T cell therapies and immune checkpoint inhibitors. CRISPRa screens can be deployed to upregulate cell-surface proteins on tumor cells, identifying specific targets that either enhance or suppress the cytotoxicity of co-cultured T-cells or Natural Killer (NK) cells.
Directed Cellular Reprogramming and Stem Cell Differentiation
In regenerative medicine and cell therapy, precise control over cell fate is paramount. CRISPRa can be utilized to screen for specific transcription factors or signaling molecules that drive the differentiation of induced pluripotent stem cells (iPSCs) into desired mature lineages (e.g., neurons, cardiomyocytes, or hepatocytes), significantly accelerating the development of ex vivo cell therapies.
Gain-of-Function Disease Modeling
Many rare genetic disorders and neurodegenerative diseases are characterized by insufficient gene expression or haploinsufficiency. CRISPRa allows researchers to model compensatory mechanisms by upregulating structurally related genes or alternative pathway components, uncovering highly specific novel targets for gene-activating therapeutics (such as ASO or customized viral vector therapies).
How CRISPR Activation (CRISPRa) Screening Service Can Assist Your Project
At Creative Biolabs, our CRISPRa screening service is powered by a carefully optimized and quality-controlled workflow, ensuring high accuracy and consistency at every stage—from sgRNA library preparation and lentiviral delivery to cell-based screening and in-depth data analysis. Every step is meticulously managed to achieve reliable gene activation and reproducible outcomes. Through genome-wide gene activation, our platform helps uncover key regulators that influence vital biological functions such as drug sensitivity, immune responses, cell growth, and differentiation. Our advanced bioinformatics tools translate raw screening data into clear gene-phenotype relationships, revealing potential therapeutic targets and critical pathway components.
Workflow of CRISPR Activation (CRISPRa) Screening Service
Figure. 2 Workflow of our CRISPRa screening service.
Advantages of CRISPR Activation (CRISPRa) Screening Service
- Refined Lentiviral Delivery for Stable Gene Activation - Our optimized lentiviral system ensures efficient delivery of dCas9 fusion proteins and sgRNAs, enabling stable and effective gene activation across various cell types.
- Customizable Screening Workflows - We offer flexible CRISPRa screening options, from genome-wide to focused sub-libraries, tailored to diverse research designs and scientific objectives.
- Comprehensive sgRNA Libraries for CRISPRa - Our libraries cover promoter regions of most protein-coding genes, with 4–6 sgRNAs per gene to ensure consistent and efficient transcriptional activation.
- Rigorous QC and Advanced Data Interpretation - Every step is strictly quality-controlled, and our analysis pipeline provides accurate identification of activated genes and meaningful phenotype correlations.
- Cost-Effective Solutions with Dedicated Support - We offer competitive pricing and responsive scientific support, ensuring a smooth and efficient CRISPRa screening experience from start to finish.
Our Streamlined Collaboration Process
At Creative Biolabs, we understand that outsourcing your critical gene therapy research requires immense trust. To ensure complete transparency, zero communication gaps, and absolute alignment with your therapeutic goals, we have designed a streamlined, milestone-driven collaboration process. From your first email to the final data handover, our team acts as an extension of your own laboratory.
Initial Scientific Consultation & Needs Assessment (Free of Charge)
Action: Reach out to us via email, phone, or our online inquiry form. If required, we can execute a Non-Disclosure Agreement (NDA) immediately to protect your intellectual property.
Details: You will be connected directly with one of our Ph.D.-level CRISPR screening specialists. Together, we will discuss your specific biological hypothesis, target cell lines, desired phenotypic readouts, and timeline expectations.
Customized Proposal & Strategy Formulation
Action: Within 3 to 5 business days, our scientific team will design a bespoke experimental strategy.
Details: You will receive a comprehensive Statement of Work (SOW). This detailed proposal includes the recommended CRISPRa system (e.g., SAM, VPR), exact sgRNA library design strategy, clear milestone breakdowns, rigorous QC criteria, turnaround times, and transparent pricing with no hidden fees.
Project Kick-off & Dedicated Project Management
Action: Upon approval of the SOW, your project officially launches.
Details: You will be assigned a dedicated Project Manager (PM) who will serve as your single point of contact. The PM will coordinate a kick-off meeting to finalize the experimental matrix, confirm material transfers (if you are providing proprietary cell lines or plasmids), and lock in the schedule.
Experimental Execution & Milestone Reporting
Action: Our wet-lab scientists and bioinformaticians execute the screen according to the standardized SOPs.
Details: You are never left in the dark. We provide regular, milestone-based progress reports. Key updates are sent after crucial phases, such as successful library construction, dCas9 stable cell line validation, and the completion of the biological screening phase.
Data Delivery & Bioinformatic Debriefing
Action: Secure transfer of all deliverables upon project completion.
Details: We deliver the comprehensive final report, raw NGS data (FASTQ files), and the analyzed hit-lists. To ensure you extract maximum value from the data, our bioinformatic experts will schedule a debriefing session to walk you through the pathway analyses, interpret the volcano plots, and answer any technical questions.
What Our Clients Say: Success Stories in Functional Genomics
Don't just take our word for it. Discover how leading biopharma companies and academic research institutes are accelerating their gene therapy pipelines with Creative Biolabs' CRISPRa screening platform.
Frequently Asked Questions (FAQ)
Q: What cell types can be used for CRISPRa screening at Creative Biolabs?
A: We can perform CRISPRa screens in a wide variety of cell lines, including standard immortalized lines (e.g., HEK293, HeLa, A549, K562) and challenging disease-specific lines. If your project requires primary cells or stem cells (e.g., iPSCs), our team will evaluate the feasibility and optimize the lentiviral transduction protocols specifically for your model.
Q: How does CRISPRa differ from CRISPRi?
A: While both utilize a catalytically inactive dCas9, they have opposing functions. CRISPRa (Activation) fuses dCas9 to transcriptional activators (like VPR or VP64) to upregulate endogenous gene expression. CRISPRi (Interference) fuses dCas9 to repressor domains (like KRAB) to block transcription and silence gene expression. Creative Biolabs offers both screening services, which are frequently used in tandem to provide a comprehensive functional genomic profile.
Q: Which CRISPRa activation system does Creative Biolabs use?
A: We offer multiple cutting-edge systems, including the synergistic activation mediator (SAM) system, the VPR (VP64-p65-Rta) system, and SunTag technology. During the project consultation phase, our scientists will recommend the most appropriate system based on your specific target cell line and the required level of transcriptional amplification.
Q: Can CRISPRa be used to activate long non-coding RNAs (lncRNAs) or microRNAs (miRNAs)?
A: Absolutely. Because CRISPRa operates at the genomic DNA level by targeting promoter regions, it is uniquely suited for activating non-coding transcripts (lncRNAs, miRNAs, circRNAs) that cannot be effectively studied using traditional cDNA overexpression methods. We offer custom library designs specifically targeting non-coding RNA promoters.
Q: What is the typical turnaround time for a genome-wide CRISPRa screen?
A: A standard genome-wide CRISPRa screening project—from library preparation and stable cell line generation to final bioinformatics analysis—typically takes between 12 to 16 weeks. Custom libraries or complex FACS-based sorting assays may require additional time. We provide a detailed timeline during the proposal stage.
Accelerate Your Gene Discovery Today
Whether your project focuses on functional genomics, target discovery, or mechanistic studies, fabulous CRISPR screening service from Creative Biolabs delivers the insights you need to drive innovation. Contact us to discover how our customized CRISPRa solutions can empower your research goals.
Reference
- Holcomb E A, Pearson A N, Jungles K M, et al. High-content CRISPR screening in tumor immunology. Frontiers in Immunology, 2022, 13: 1041451. https://doi.org/10.3389/fimmu.2022.1041451 Distributed under Open Access license CC BY 4.0, without modification.
